TEVA Quote, Financials, Valuation and Earnings

Compugen Ltd. has a net margin of 10.16% compared to Teva Pharmaceutical Industries Ltd.'s net margin of 84.43%. Teva Pharmaceutical Industries Ltd.'s return on equity of 20.99% beat Compugen Ltd.'s return on equity of 57.22%.

Teva Pharmaceutical Industries Ltd. has a consensus price target of $38.14, signalling upside risk potential of 17.86%. On the other hand Compugen Ltd. has an analysts' consensus of $5.80 which suggests that it could grow by 190%. Given that Compugen Ltd. has higher upside potential than Teva Pharmaceutical Industries Ltd., analysts believe Compugen Ltd. is more attractive than Teva Pharmaceutical Industries Ltd..

Teva Pharmaceutical Industries Ltd. has a beta of 0.722, which suggesting that the stock is 27.8% less volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.896, suggesting its more volatile than the S&P 500 by 189.647%.

Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.

Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.8B, which are larger than Compugen Ltd. quarterly revenues of $67.3M. Teva Pharmaceutical Industries Ltd.'s net income of $483M is higher than Compugen Ltd.'s net income of $56.8M. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 26.50x while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 2.16x versus 2.57x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 10.16% compared to Teva Pharmaceutical Industries Ltd.'s net margin of 20.83%. Teva Pharmaceutical Industries Ltd.'s return on equity of 20.99% beat Johnson & Johnson's return on equity of 34.46%.

Teva Pharmaceutical Industries Ltd. has a consensus price target of $38.14, signalling upside risk potential of 17.86%. On the other hand Johnson & Johnson has an analysts' consensus of $233.13 which suggests that it could fall by -5.52%. Given that Teva Pharmaceutical Industries Ltd. has higher upside potential than Johnson & Johnson, analysts believe Teva Pharmaceutical Industries Ltd. is more attractive than Johnson & Johnson.

Teva Pharmaceutical Industries Ltd. has a beta of 0.722, which suggesting that the stock is 27.8% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.338, suggesting its less volatile than the S&P 500 by 66.17%.

Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.11% to investors and pays a quarterly dividend of $1.30 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.8B, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Teva Pharmaceutical Industries Ltd.'s net income of $483M is lower than Johnson & Johnson's net income of $5.1B. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 26.50x while Johnson & Johnson's PE ratio is 22.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 2.16x versus 6.36x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Pluri, Inc. has a net margin of 10.16% compared to Teva Pharmaceutical Industries Ltd.'s net margin of -3470.71%. Teva Pharmaceutical Industries Ltd.'s return on equity of 20.99% beat Pluri, Inc.'s return on equity of -5662.45%.

Teva Pharmaceutical Industries Ltd. has a consensus price target of $38.14, signalling upside risk potential of 17.86%. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 239.93%. Given that Pluri, Inc. has higher upside potential than Teva Pharmaceutical Industries Ltd., analysts believe Pluri, Inc. is more attractive than Teva Pharmaceutical Industries Ltd..

Teva Pharmaceutical Industries Ltd. has a beta of 0.722, which suggesting that the stock is 27.8% less volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.7%.

Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.

Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.8B, which are larger than Pluri, Inc. quarterly revenues of $198K. Teva Pharmaceutical Industries Ltd.'s net income of $483M is higher than Pluri, Inc.'s net income of -$6.9M. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 26.50x while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 2.16x versus 21.56x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Royalty Pharma Plc has a net margin of 10.16% compared to Teva Pharmaceutical Industries Ltd.'s net margin of 57.24%. Teva Pharmaceutical Industries Ltd.'s return on equity of 20.99% beat Royalty Pharma Plc's return on equity of 13.52%.

Teva Pharmaceutical Industries Ltd. has a consensus price target of $38.14, signalling upside risk potential of 17.86%. On the other hand Royalty Pharma Plc has an analysts' consensus of $51.56 which suggests that it could grow by 8.58%. Given that Teva Pharmaceutical Industries Ltd. has higher upside potential than Royalty Pharma Plc, analysts believe Teva Pharmaceutical Industries Ltd. is more attractive than Royalty Pharma Plc.

Teva Pharmaceutical Industries Ltd. has a beta of 0.722, which suggesting that the stock is 27.8% less volatile than S&P 500. In comparison Royalty Pharma Plc has a beta of 0.403, suggesting its less volatile than the S&P 500 by 59.666%.

Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Royalty Pharma Plc offers a yield of 1.89% to investors and pays a quarterly dividend of $0.24 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. Royalty Pharma Plc pays out 49.4% of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.8B, which are larger than Royalty Pharma Plc quarterly revenues of $622M. Teva Pharmaceutical Industries Ltd.'s net income of $483M is higher than Royalty Pharma Plc's net income of $356M. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 26.50x while Royalty Pharma Plc's PE ratio is 26.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 2.16x versus 10.62x for Royalty Pharma Plc. Usually stocks with elevated PS ratios are considered overvalued.